Q1 2025

Source filing unavailable

Q1 2025 · —

Revenue

$330.00K

no prior Q1 2024 on file

Net Income

-$1.20M

no prior Q1 2024 on file

EPS Diluted

-$0.02

no prior Q1 2024 on file

Gross Profit$154,000—

Operating Income-$1,413,000—

Operating Cash Flow-$730,000

Same quarter

Metric	Q1 2025	Q1 2022	Q1 2021	Q1 2020
Revenue	$330.00K	$77.00K	$584.00K	$1.65M
Net Income	-$1.20M	-$1.79M	-$1.88M	-$1.38M
EPS Diluted	-$0.02	-$0.04	-$0.05	-$0.03

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

IGC Pharma, Inc. · CIK 1326205 · Engraved from SEC EDGAR